Alnylam Pharmaceuticals Inc (ALNY)

Alnylam Pharmaceuticals, Inc. is a biotechnology company listed on NASDAQ under the ticker ALNY. The company focuses on RNA interference-based medicines and operates in the United States, Europe, and other international markets. Its commercial portfolio includes ONPATTRO, AMVUTTRA, Leqvio, Qfitlia, GIVLAARI, and OXLUMO, which are used across several rare and genetic disease areas, including amyloidosis, hemophilia, acute hepatic porphyria, and primary hyperoxaluria type 1.

Alnylam also has a pipeline that spans multiple development stages. Its late-stage programs include candidates for ATTR amyloidosis, hypertension, myasthenia gravis, paroxysmal nocturnal hemoglobinuria, geographic atrophy, and hepatitis D. Additional programs in earlier trials target conditions such as metabolic dysfunction-associated steatohepatitis, diabetic kidney disease, type 2 diabetes, cerebral amyloid angiopathy, bleeding disorders, obesity, dyslipidemia, Huntington’s disease, Parkinson’s disease, polycythemia vera, and hepatocellular carcinoma. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.